P 53, which is the "cellular gatekeeper for growth and division," 1 controls cell proliferation by causing cell cycle arrest and apoptosis through induction of p53-responsive genes.
2 p53 is the most commonly mutated gene in human cancer, 3 and inactivation of p53 protein contributes not only to tumor progression 4 but also to the resistance of cancer cells to ionizing radiation and chemotherapy. 5 Therefore, p53 is the first tumor suppressor gene that has been used for gene therapy of malignant diseases. 6 The targets for p53-based gene therapy consist of tumors in which p53 is inactivated. [7] [8] [9] [10] The most frequent mechanism of p53 inactivation is induction of missense mutations in one p53 allele and deletion of the other one. 3, 11 The resultant p53 mutant acts as a neutralizing dominant-negative molecule by hetero-oligomerization with wild-type (wt) p53. 12 However, wt p53 is inactivated by several other mechanisms. First, the murine double minute-2 (MDM2) gene encodes a nuclear phosphoprotein that inhibits p53-mediated transactivation 13, 14 and promotes the degradation of p53. 15, 16 Furthermore, transcriptional activation of the MDM2 gene is induced by p53; 17 therefore, MDM2 has been proposed to regulate p53 by a negativefeedback-loop mechanism. 18 The MDM2 gene is frequently amplified in human sarcomas 19 -24 and breast carcinomas, [25] [26] [27] [28] and to a lesser extent in lung carcinomas 29, 30 and oral squamous cell carcinomas, 31 giving rise to a functional null phenotype for the p53 gene. Second, the high-risk human papillomaviruses (HPVs) that are implicated in the pathogenesis of cervical cancers 32 produce the E6 protein, which stimulates the inactivation 33 and ubiquitin-dependent degradation of p53. 34 Third, p53 is also known to be inactivated by the X protein, 35, 36 produced by hepatitis B virus (HBV), which is implicated in the pathogenesis of liver cancer. 37 In summary, p53 mutations, MDM2 overexpression, and HPV or HBV infections are alternative mechanisms for inactivating the same regulatory pathway that suppresses cell growth. However, MDM2 overexpression as well as HPV or HBV infections are situations in which it would not be favorable to introduce an exogenous wt p53 that could be inactivated. Therefore, it would be advantageous to have access to p53 analogs that would be insensitive to inactivation and degradation. Such a p53 analog, namely chimeric tumor suppressor 1 (CTS1), has been designed and characterized recently. 38 In this construct, the domains of p53 that mediate its inactivation and/or degradation (i.e., the NH 2 -and COOH-terminal domains that were shown to be functionally replaceable with foreign transactivation and oligomerization domains, respectively) 39 have been sub-stituted with heterologous sequences. It has been shown that, in vitro, CTS1 retains the ability to act as a transcriptional transactivator and as a cell growth suppressor in contexts in which wt p53 was found to be inefficient. This synthetic tumor suppressor gene should not only increase the efficiency of gene therapy, but also expand the range of cancers amenable to treatment.
In the present study, we evaluated the antitumoral activity of CTS1 mediated by adenovirus vector in comparison with a wt p53 adenovirus vector in various human tumor cell lines. We showed that, both in vitro and in vivo in nude mice, CTS1 adenovirus has significantly higher antitumoral growth activity than p53 adenovirus in a human osteosarcoma tumor model expressing endogenous wt p53 and overexpressing MDM2. This higher efficacy was correlated with a higher induction of apoptosis.
MATERIALS AND METHODS

Construction and preparation of recombinant adenovirus
For construction of the AV1.0CMV.CTS1 adenovirus containing the CTS1 gene (AV.CTS1), the CTS1 cDNA 38 was fused to a simian virus 40 late polyadenylation signal and cloned downstream of the cytomegalovirus (CMV) immediate early promoter. The complete expression unit was inserted into a suicide shuttle vector. The recombinant human Ad5 adenoviral genome (deleted in the E1 and E3 regions) was generated by homologous recombination in Escherichia coli 40 and was subsequently transfected in 293 cells. The recombinant AV.CTS1 virus was analyzed by restriction mapping, DNA sequencing of the expression cassette, and Southern and Western blotting analyses. We used the same technology for construction of the control AV1.0CMV adenovirus (AV.empty) containing the CMV immediate early promoter flanked by the simian virus 40 late polyadenylation signal without any inserted transgene. The Ad5CMV-p53 adenovirus containing the p53 gene driven by the CMV promoter (Ad-p53) was constructed as described previously. 7 Preclinical batches of purified virus were prepared in 293 cells (CRL-75; American Type Culture Collection (ATCC), Manassas, Va) cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS) at 37°C and 5% CO 2 in rollers. Supernatants of 293 infected cells were recovered 10 days postinfection after complete cytopathic effect and cell autolysis. After removing cell debris by depth filtration, clarified supernatants were concentrated on trefoil factor family membranes (Pre-Scale TFF; Millipore, Bedford, Mass) and subjected to two rounds of CsCl-step gradient purification. After desalting through Sephadex G25 columns (PD10; Amersham Pharmacia Biotechnology, Arlington Heights, Ill), purified viruses were formulated in deionized PBS containing 10% glycerol, 0.5 mM MgCl 2 , and 0.5 mM CaCl 2 and stored at Ϫ70°C. Titers of viral stocks were determined by PFU assay on 293 cells and by high-performance liquid chromatography for VP.
Cell culture and infection
The human lung carcinoma cell lines (H460, H1299, and H358), osteosarcoma cell lines (U-2OS, SA1, and Saos-2), and breast carcinoma cell lines (MCF-7, ZR-75-1, T-47D, and SK-BR-3) obtained from ATCC were cultured in RPMI 1640 medium supplemented with 10% FCS at 37°C and 5% CO 2 
Cell cycle analysis
At 24 hours postinfection, cells were recovered by trypsin/ EDTA digestion. After membrane permeabilization with 0.15% saponin in PBS, cells were fixed in methanol. For detection of DNA content, propidium iodide (Sigma, St. Louis, Mo) was added to a final concentration of 10 g/mL in the presence of 100 g/mL ribonuclease A (Boehringer Mannheim, Indianapolis, Ind). Flow cytometric analysis was performed with a FACScalibur flow cytometer (Becton Dickinson). At least 10,000 cells were counted to determine the percentage of cells in each phase of the cell cycle, and this percentage was calculated with ModFit cell cycle analysis software (Verity Software House, Becton Dickinson).
Detection of apoptosis
Detection of apoptotic cells by flow cytometry was performed by terminal deoxyribonucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining, using the in situ cell death detection kit (Boehringer Mannheim) as described by the manufacturer. Briefly, at 48 hours postinfection, both cells in supernatant (by centrifugation) and adherent cells (by trypsin/EDTA digestion) were recovered and fixed in 1% formaldehyde. After membrane permeabilization with 0.2% Triton X-100 in PBS, fluorescein isothiocyanate-labeled deoxynucleotides were incorporated by TdT to free 3Ј-OH DNA ends produced by DNA fragmentation during infection. Fluorescence was measured with a FACScalibur flow cytometer (Becton Dickinson). At least 10,000 cells were counted to determine the fraction of TUNEL-positive cells. Each value is the mean of a triplicate.
Antitumoral activity in nude mice
SA1 tumors were induced in 6-to 7-week-old athymic nu/nu Swiss mice on day 0 by subcutaneous injection of 5 ϫ 10 6 cells into the right flanks of mice. When tumors reached a volume of 50 -150 mm 3 , treatment of animals (n ϭ 10) was initiated by intratumoral (i.t.) injection of adenovirus in a volume of 20 -32 L/tumor. Five i.t. administrations of 6 ϫ 10 10 VP were delivered daily into tumors (days 11-15) in two to three discrete tumor sites. Tumors were measured in three orthogonal dimensions with a caliper three times a week, and volumes were estimated assuming an ellipsoid shape as follows:
The antitumoral effects of CTS1 and p53 adenovirus were determined by their ability to delay tumor growth. Tumor growth delay (T-C) was defined as the difference between vehicle-and adenovirus-treated tumors in the median time to reach a tumor volume of 1000 mm 3 . The time to reach 1000 mm 3 was compared between vehicle-and adenovirus-treated tumors and between AV.empty and AV.CTS1-or Ad-p53-treated tumors using a two-tailed Mann-Whitney nonparametric rank test.
Immunohistochemical analysis
Mice were treated as described above (n ϭ 3 animals for each treatment). At 24 hours after the first i.t. injection, mice were sacrificed by cervical dislocation. Tumors and surrounding tissues were removed after skin incision using scissors and forceps, and samples were fixed for 5 hours in 3.7% formaldehyde. In situ immunohistochemistry was done using serial 5-m paraffin-embedded tumor sections. Hematoxylin and eosin and safran (HES) staining was performed as described previously. 41 Immunostaining was performed using the avidinbiotin-peroxidase complex method as described previously, 42 using primary mouse mAbs (one directed against MDM2 (clone IF2, Oncogene Science) and one directed against the p53 core domain, which recognizes both p53 and CTS1 (clone PAb 240, Oncogene Science)). Diaminobenzidine was used as the chromogen, and slides were counterstained with hematoxylin. Detection of apoptotic cells was performed by TUNEL staining using the in situ cell death detection kit (Boehringer Mannheim) as described previously. 43 Slides were counterstained with hematoxylin.
RESULTS
In vitro inhibition of cell growth
Various human tumor cell lines (derived from non-small cell lung carcinoma, osteosarcoma, and breast carcinoma), either deleted for p53 or expressing endogenous wt or mutated p53, have been studied. The p53 status of these cells was determined using a p53 functional yeast assay (our unpublished results). 44 Overexpression of endogenous MDM2 has been described in some of these cell lines, such as the human osteosarcoma cell line SA1 (also known as Osa-CL) 19, 20, 22 and to a lesser extent in the human breast carcinoma cell lines ZR-75-1 and MCF-7. 25 We evaluated the inhibition of cell growth and calculated the efficiency dose (MOI in VP/cell) required to observe 50% of cell growth inhibition (ED 50 ) in the presence of different adenoviral vectors (control AV.empty, Ad-p53, and AV.CTS1). Results are summarized in Table 1 . In deleted or mutated p53 tumor cells, AV.CTS1 was significantly less efficient (2-to 9-fold) than Ad-p53 (T-47D, Saos-2, H1299, H358, and SK-BR-3 cell lines), whereas in wt p53 tumor cells that do Ͼ10,000 700 Ϯ 7 5,000 Ϯ 0 Ͼ7 ϫ (P Ͻ .01)
NSCLC, non-small cell lung carcinoma; OS, osteosarcoma; BC, breast carcinoma. Inhibition of cell growth studies were conducted using increased MOIs of control AV.empty, AV.CTS1, or Ad-p53 adenovirus to infect cell monolayers as described in Materials and Methods. The number of viable cells was quantitated at 72 hours postinfection by staining with crystal violet. Results show the ED 50 , which is the efficiency dose (MOI in VP/cell) required to inhibit 50% of cell growth. Results represent the mean Ϯ SD of two to four independent experiments done in triplicate. Results with CTS1 and p53 adenovirus were compared for statistical significance using the Mann-Whitney nonparametric rank test (P value). not express inhibitors of p53, AV.CTS1 was as efficient as Ad-p53 (U-2OS and H460 cell lines). Interestingly, in tumor cells expressing wt endogenous p53 and overexpressing MDM2, AV.CTS1 was significantly more efficient (2-to 7-fold) than Ad-p53 (MCF-7, ZR-75-1, and SA1 cell lines).
To correlate the inhibition of cell growth with the level of transgene expression, we measured the transgene expression in each cell line using an antibody recognizing both p53 and CTS1 and then calculated the infectious dose (MOI in VP/cell) required to get 50% of the cells to express the transgene (ID 50 ) ( Table 2) . Interestingly, when calculating the ED 50 / ID 50 ratio, we observed that for Ad-p53, this ratio was on average 0.5 for the mutated or deleted p53 cells and 2 for the wt p53 cells. This suggests that mutated or deleted p53 cells are more sensitive to Ad-p53 (4-fold) than wt p53 cells. In contrast, for AV.CTS1, the ED 50 /ID 50 ratio was on average 2 for both mutated or deleted p53 cells and wt p53 cells, suggesting that AV.CTS1 has the same efficiency regardless of p53 status. This confirms the hypothesis that CTS1 is a constitutively active protein.
In vitro induction of G 1 cell cycle arrest and apoptosis
To determine the mechanism of action of AV.CTS1 compared with Ad-p53, we investigated the induction of cell cycle arrest and apoptosis. These studies were performed in three representative cell lines, H1299 (non-small cell lung carcinoma cell line, deleted for p53), H460 (non-small cell lung carcinoma cell line expressing wt p53 and mutated Ras), and SA1 (osteosarcoma cell line expressing wt p53 and overexpressing MDM2).
Regarding the induction of cell cycle arrest (Fig 1) , AV.CTS1 induced a weaker G 1 cell cycle arrest (24% increase of G 1 cells) than Ad-p53 (57% increase) in the H1299 cells. Furthermore, a fraction of cells with a DNA content less than the G 1 cells (which might reflect a fraction of apoptotic cells) was observed after infection with Ad-p53 (17% of the whole population) but not after infection with AV.CTS1. In contrast, both AV.CTS1 and Ad-p53 induced equal G 1 cell cycle arrest (a 37% and 47% increase, respectively) in H460 cells. Interestingly, in SA1 cells, only Ad-p53 induced a G 1 arrest (39% increase), and a fraction of potentially apoptotic cells (25% of the whole population) was observed only with AV.CTS1.
Regarding the induction of apoptosis (Fig 2) , we observed that AV.CTS1 induced less apoptosis than Ad-p53 in H1299 cells (11-fold), whereas it induced more apoptosis than Ad-p53 in SA1 cells (6-fold). In H460 cells, no significant difference was observed between AV.CTS1 and Ad-p53, which both induced apoptosis.
Therefore, we confirmed that Ad-p53 was more efficient than AV.CTS1 in deleted p53 tumor cells due to higher induction of both G 1 cell cycle arrest and apoptosis, whereas AV.CTS1 was more efficient than Adp53 in wt p53 tumor cells overexpressing MDM2 due to higher induction of apoptosis without any induction of 
In vivo inhibition of tumor growth
To confirm the potential advantage of CTS1 over p53 in the context of MDM2 overexpression, we compared the tumor growth inhibition induced by CTS1 or p53 adenovirus injected in pre-established tumors developed in nude mice from SA1 osteosarcoma cells, which express endogenous wt p53 and overexpress MDM2.
As shown in Figure 3 , inhibition of tumor growth was observed with both AV.CTS1 and Ad-p53 adenovirus. Both constructs led to a complete block of tumor growth for at least 18 days with AV.CTS1 compared with 14 days with Ad-p53, whereas no effect was induced by the control AV.empty adenovirus. This tumor growth arrest did not persist, and tumors relapsed more rapidly for Ad-p53-treated tumors than for AV.CTS1-treated ones. This antitumoral efficacy was dose-dependent for both the CTS1 and p53 vectors (data not shown).
The in vivo results are summarized in Table 3 . At the highest dose, AV.CTS1 adenovirus was significantly (P Ͻ .05) more efficient than Ad-p53, with a tumor Figure 1 . In vitro effect of CTS1 and p53 gene transfer on cell cycle regulation. Cells were infected with either control AV.empty, AV.CTS1, or Ad-p53 adenovirus at an MOI of 500 VP/cell for H1299 cells, 10,000 VP/cell for H460 cells, and 2,000 VP/cell for SA1 cells. Noninfected cells were followed as a control (mock). At 24 hours postinfection, cells were analyzed for DNA content by propidium iodide staining using flow cytometry. Each phase of the cell cycle (G 1 , S, and G 2 /M) is indicated. The percentage of cells in each phase of the cell cycle (G 1 , S, and G 2 /M) was calculated, as indicated.
growth delay of 25.6 days compared with 12.4 days for Ad-p53 adenovirus and 0.5 days for AV.empty adenovirus.
In vivo induction of apoptosis
To further investigate the mechanism of this tumor growth inhibition, we performed immunohistochemical analyses of the adenovirus-treated SA1 osteosarcoma tumor, looking at transgene expression, endogenous MDM2 overexpression, and induction of apoptosis.
First, to prove that tumor growth inhibition was related to transgene expression, AV.CTS1-and Ad-p53-treated tumors were processed for immunohistochemistry using the same anti-p53 mAb that recognizes both p53 and CTS1. The extent of transgene expression throughout tumors was similar after infection with both AV.CTS1 and Ad-p53. This expression was not diffused in the whole tumor, but was localized in a distinct tumor area (two to three areas corresponding to the two to three injection sites) and represented 10 -20% of the whole tumor.
Next, we confirmed the amplification of MDM2 protein in SA1 tumor sections in situ by immunohistochemistry. We observed an expression of endogenous MDM2 protein in noninfected areas (Fig 4, b and f) , whereas the sensitivity of our method did not allow the detection of any endogenous p53 protein expression (Fig 4, a and e) . Furthermore, this endogenous MDM2 protein expression was greatly enhanced in both AV.CTS1-and Adp53-infected tumor areas (Fig 4, b and f, respectively) and colocalized with the transgene expression (Fig 4, a  and e, respectively) . This AV.CTS1/Ad-p53-induced MDM2 overexpression was not observed after infection with the control AV.empty adenovirus (data not shown).
Analysis of tumor histopathology showed fragmented cells in both the AV.CTS1-infected tumor area (Fig 4c,  upper right) and the Ad-p53-infected tumor area (Fig  4g, upper right) , whereas no significant histological difference was observed in the noninfected tumor area. The presence of fragmented cells strictly colocalized with both transgene expression (Fig 4, a and e) and TUNEL immunostaining (Fig 4, d and h ), demonstrating that this cell death was due to a specific induction of p53-dependent apoptosis. Furthermore this induction of apoptosis was significantly higher in AV.CTS1-treated tumors (10% of the whole tumor) compared with Adp53-treated tumors (3% of the whole tumor). Few apoptotic cells (as assessed by HES and TUNEL staining) were observed after infection with the control AV.empty adenovirus (Ͻ1% of the whole tumor); this result was also observed in nontreated tumors and might be due to spontaneous cell death (data not shown).
Therefore, the higher tumor growth inhibition induced by CTS1 adenovirus compared with p53 adenovirus, observed in the osteosarcoma SA1 tumor model overexpressing MDM2, was correlated with a higher induction of apoptosis.
DISCUSSION
We have designed a p53 analog, CTS1, which is potentially resistant to inactivation by inhibitors of p53 such as MDM2. In vitro, in terms of tumor growth inhibition (see Table 1 ), we have shown an advantage of AV.CTS1 adenovirus treatment over Ad-p53 adenovirus treatment in tumor models expressing endogenous wt p53 and overexpressing MDM2. In contrast, we have observed that in tumors harboring nonfunctional p53 (deleted or mutated), Ad-p53 was more efficient than AV.CTS1. Finally, in wt p53 tumors that do not overexpress inhibitors of p53 but express another mutated oncogene (e.g., Ras), the efficiency of AV.CTS1 and Ad-p53 was equivalent, but was significantly lower than their activity in MDM2-overexpressing and mutated p53 tumor models, respectively.
Investigating the mechanism of action of CTS1 versus p53 in vitro (see Figs 1 and 2) , we have shown that the higher efficiency of Ad-p53 observed in tumors harboring nonfunctional p53 was caused by an increased induction of both cell cycle arrest and cell death. In contrast, in tumors overexpressing MDM2 (SA1 osteosarcoma), we have shown that the higher efficiency of AV.CTS1 is due to an increased induction of apoptosis, whereas there was no significant induction of G 1 cell cycle arrest.
We proposed that, in SA1 tumors, the massive induction of apoptosis in response to CTS1 expression might overcome induction of G 1 cell cycle arrest. Indeed, it has been reported that the p53-mediated apoptotic pathway is dominant over the growth arrest pathway. 45 The antitumoral activity of AV.CTS1 was further confirmed in vivo in pre-established tumors developed in nude mice (see Fig 3 and Table 3 ). In an osteosarcoma model expressing endogenous wt p53 and overexpressing MDM2, we have shown higher tumor growth inhibition with AV.CTS1 compared with Ad-p53. This higher efficiency was correlated with a higher induction of apoptosis (see Fig 4, d and h ). However, although we observed a strong effect at the microscopic level in AV.CTS1-treated tumors (see Fig 4, c and d) , at this level of tumor growth we only observed a delay in tumor growth, but not tumor regression. This result could be explained by the relatively low level of transgene expression throughout the tumor, presumably due to a limited diffusion of adenovirus. Two to three infected areas were observed representing 10 -20% of the whole tumor and colocalizing with injection sites.
Taken together, our results allow us to propose CTS1 gene therapy as an alternative to p53 gene therapy. Approximately 50% of all human tumors have lost their p53 function; therefore, cancer gene therapy has focused on reintroduction of a functional p53 gene into these tumors. However, it has been reported previously that Ad-p53 displays a lower antitumoral activity in tumors harboring wt p53 compared with tumors harboring mutated or deleted p53 (our unpublished results). 46 This observation remains to be explained. Our results suggest that tumors harboring wt p53 might be resistant to p53 gene therapy due to overexpression of inhibitors of p53, which then leads to inactivation of both the endogenous p53 and the reintroduced exogenous p53. Therefore, p53 gene therapy may not be universally applied and may be only successfully targeted to mutated or deleted p53 tumors, whereas CTS1 gene therapy could be successfully targeted to wt p53 tumors overexpressing inhibitors of p53 such as MDM2. A CTS1 gene therapy aproach could also be potentially extended to tumors expressing other inhibitors of p53, such as the E6/HPV or X/HBV proteins. SA1 tumors were induced at day 0 and processed as described in Figure 3 . T-C represents the tumor growth delay between vehicleand adenovirus-treated tumors. P represents the statistical comparison of time to reach 1000 mm 3 between vehicle-and adenovirustreated tumors (p1) and between AV.empty and AV.CTS1-or Ad-p53-treated tumors (p2), using the Mann-Whitney nonparametric rank test. Figure 4 . In vivo effect of CTS1 and p53 gene transfer on SA1 osteosarcoma tumor histopathology. The effect of CTS1 and p53 gene transfer on SA1 tumor growth in nude mice (n ϭ 3) was assessed as described in Figure  3 . In situ immunohistochemical analyses were performed 24 hours after the first adenovirus injection on 5-m serial tumor sections from either the AV.CTS1-treated group (a-d) or the Ad-p53-treated group (e-h). We analyzed p53 immunostaining (a,e), MDM2 immunostaining (b,f), HES staining (c,g), and TUNEL staining (d,h), with a magnification of ϫ40. The white dotted line defines the infected area (upper right) and the noninfected area as an internal negative control (lower left).
